Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 3;10(5):1030.
doi: 10.3390/jcm10051030.

Efficacy and Safety of Tranexamic Acid in Emergency Trauma: A Systematic Review and Meta-Analysis

Affiliations

Efficacy and Safety of Tranexamic Acid in Emergency Trauma: A Systematic Review and Meta-Analysis

Mahdi Al-Jeabory et al. J Clin Med. .

Abstract

In trauma patients, bleeding can lead to coagulopathy, hemorrhagic shock, and multiorgan failure, and therefore is of fundamental significance in regard to early morbidity. We conducted a meta-analysis to evaluate the efficacy and safety of tranexamic acid (TXA) in civil and military settings and its impact on in-hospital mortality (survival to hospital discharge or 30-day survival), intensive care unit and hospital length of stay, incidence of adverse events (myocardial infarct and neurological complications), and volume of blood product transfusion. The systematic review and meta-analysis were conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A systematic review of the literature using PubMed, Scopus, EMBASE, Web of Science, and the Cochrane Central Register and Controlled Trials (CENTRAL) database was conducted from inception to 10 January 2021. In-hospital mortality was reported in 14 studies and was 15.5% for the TXA group as compared with 16.4% for the non-TXA group (OR = 0.81, 95% CI 0.62-1.06, I2 = 83%, p = 0.12). In a civilian TXA application, in-hospital mortality in the TXA and non-TXA groups amounted to 15.0% and 17.1%, respectively (OR = 0.69, 95% CI 0.51-0.93, p = 0.02, I2 = 78%). A subgroup analysis of the randomized control trial (RCT) studies showed a statistically significant reduction in in-hospital mortality in the TXA group (14.3%) as compared with the non-TXA group (15.7%, OR = 0.89, 95% CI 0.83-0.96, p = 0.003, I2 = 0%). To summarize, TXA used in civilian application reduces in-hospital mortality. Application of TXA is beneficial for severely injured patients who undergoing shock and require massive blood transfusions. Patients who undergo treatment with TXA should be monitored for clinical signs of thromboembolism, since TXA is a standalone risk factor of a thromboembolic event and the D-dimers in traumatic patients are almost always elevated.

Keywords: bleeding; emergency medicine; meta-analysis; mortality; systematic review; tranexamic acid; trauma.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Meta-analysis flow chart of included and excluded studies.
Figure 2
Figure 2
Forest plot of in-hospital mortality in the TXA group vs. non-TXA group. (a) Combat injuries; (b) Civilian injuries. The center of each square represents the weighted odds ratio (OR) for individual trials, and the corresponding horizontal line stands for the 95% confidence interval (CI). The diamonds represent pooled results.
Figure 3
Figure 3
Forest plot of in-hospital mortality in the TXA group vs. the non-TXA group. (a) Randomized control trials (RCTs); (b) Non-randomized control trials. The center of each square represents the weighted odds ratio (OR) for individual trials, and the corresponding horizontal line stands for the 95% confidence interval (CI). The diamonds represent pooled results.

Similar articles

Cited by

References

    1. Kool B., Lilley R., Davie G., Reid P., Civil I., Branas C., de Graaf B., Dicker B., Ameratunga S.N. Evaluating the impact of prehospital care on mortality following major trauma in New Zealand: A retrospective cohort study. Inj. Prev. 2021 doi: 10.1136/injuryprev-2020-044057. - DOI - PubMed
    1. Perel P., Prieto-Merino D., Shakur H., Clayton T., Lecky F., Bouamra O., Russell R., Faulkner M., Steyerberg E.W., Roberts I. Predicting early death in patients with traumatic bleeding: Development and validation of prognostic model. BMJ. 2012;345:e5166. doi: 10.1136/bmj.e5166. - DOI - PMC - PubMed
    1. Paudyal P., Smith J., Robinson M., South A., Higginson I., Reuben A., Shaffee J., Black S., Logan S. Tranexamic acid in major trauma. Eur. J. Emerg. Med. 2017;24:44–48. doi: 10.1097/MEJ.0000000000000323. - DOI - PubMed
    1. Al-Jeabory M., Gasecka A., Wieczorek W., Mayer-Szary J., Jaguszewski M.J., Szarpak L. Efficacy and safety of tranexamic acid in pediatric trauma patients: Evidence from meta-analysis. Am. J. Emerg. Med. 2021:1–3. doi: 10.1016/j.ajem.2021.02.009. - DOI - PubMed
    1. Frith D., Goslings J.C., Gaarder C., Maegele M., Cohen M.J., Allard S., Johansson P.I., Stanworth S., Thiemermann C., Brohi K. Definition and drivers of acute traumatic coagulopathy: Clinical and experimental investigations. J. Thromb. Haemost. 2010;8:1919–1925. doi: 10.1111/j.1538-7836.2010.03945.x. - DOI - PubMed

LinkOut - more resources